Retina
Optimizing Anti-VEGF Dosing in nAMD and DME: In Search of the Best Regimen
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Glaucoma possible after retina procedures
Patients who have undergone retina procedures have a relatively high rate of glaucoma, according to a speaker at the American Glaucoma Society meeting.
Vision improvements sustained with photobiomodulation at 24 months in dry AMD trial
Photobiomodulation delivered with the Valeda light delivery system demonstrated sustained vision improvements at 24 months in patients with dry age-related macular degeneration, according to a press release from LumiThera.
Phase 3 Pagoda trial meets primary endpoint goal for DME
The Pagoda trial has met its primary endpoint goal for diabetic macular edema, according to a speaker.
News and Views on Advances in Neovascular Retinal Disease Treatment: Weighing the Options
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Remote monitoring of macular thickness may help assess AMD
Comparing macular thickness between in-office visits can help quickly determine if clinical assessment is needed in patients with age-related macular degeneration, according to a presenter.
Biologics license application for aflibercept 8 mg receives priority review
The FDA accepted for priority review the biologics license application for aflibercept 8 mg for the treatment of wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy, according to a Regeneron press release.
Training needed for suprachoroidal drug delivery
Specialists should take the time to learn how to perform suprachoroidal injections of triamcinolone acetonide to treat macular edema due to noninfectious uveitis.
Evidence-Based Approaches to Diagnose, Treat, and Manage Patients With Retinal Diseases: Summaries of Clinical Trials
This activity is supported by independent medical education grants from AbbVie Inc.; Alcon Vision, LLC; Apellis Pharmaceuticals, Inc.; Bausch + Lomb; Genentech, a member of the Roche Group; EyePoint Pharmaceuticals, Inc.; Iveric Bio, Inc.; Regeneron Pharmaceuticals, Inc.; and Regenxbio, Inc.
Geographic Atrophy: Slowing the Progression - Rapid Response From New York
This activity is supported by an educational grant from Apellis Pharmaceuticals.